retatrutide us Lilly Prepares for FDA Filing Following Additional Phase 3 Data in Diabetes, CVD RETATRUTIDE (RETA) – Research Peptide

In December 2025, CMS announced the Medicare GLP-1 Bridge demonstration, a short-term program that will allow eligible Medicare beneficiaries to access GLP-1 obesity medications at a $50/month co-pay starting July 2026 , using a centralized processor to manage PA, claims adjudication, and payment ( [18] )

Illinois Medicaid covers Mounjaro for T2D but explicitly excludes weight-loss GLP-1s a cleaner exclusion than many states

There is some evidence that these individuals exhibit a higher risk of cancer

There are fewer than 1 million enrolled individuals in plans with coverage, less than 5% of total Marketplace enrollment